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Objective. Rheumatoid arthritis (RA) often results in deformities at the metacarpophalangeal (MCP) joints. Patients with
severe deformities can be treated by silicone metacarpophalangeal joint arthroplasty (SMPA). The objective of the study
is to prospectively compare long-term outcomes for an SMPA surgical and a nonsurgical cohort of RA patients.
Methods. A total of 67 surgical and 95 nonsurgical patients with severe subluxation and/or ulnar drift of the ﬁngers at
the MCP joints were recruited from 2004–2008 in this multicenter prospective cohort study. Patients could elect to
undergo SMPA or not. Outcomes included the Michigan Hand Outcomes Questionnaire (MHQ), Arthritis Impact Mea-
surement Scales 2 (AIMS2), grip/pinch strength, Jebsen-Taylor Test, ulnar deviation, extensor lag, and arc of motion
measurements at the MCP joints.
Results. There was no signiﬁcant difference in the mean age, race, education, and income at baseline between the 2
groups. Surgical subjects had worse MHQ function and functional measurements at baseline. At 3 years, the mean overall
MHQ score and the MHQ function, activities of daily living, aesthetics, and satisfaction scores showed signiﬁcant
improvement in the surgical group compared to the nonsurgical group. Ulnar deviation, extensor lag, and arc of motion
in the MCP and proximal interphalangeal joints also improved signiﬁcantly in the surgical group. No improvement was
seen in the mean AIMS2 scores and grip/pinch strength. Complications were minimal with a fracture rate of 9.5%.
Conclusion. RA patients with poor baseline functioning showed long-term improvement in hand function and appear-
ance following treatment with SMPA compared to nonsurgical controls.
INTRODUCTION
Inﬂammation that leads to progressive damage to joints is
a hallmark of rheumatoid arthritis (RA). The joints most
often affected are the metacarpophalangeal (MCP) joints,
with RA causing dislocation of the MCP joints and ulnar
deviation of the ﬁngers. This deformity often results in
disability because of the inability to extend the ﬁngers to
grasp objects. Treatment for RA almost always requires
medications to halt or slow the progression of joint dam-
age. Surgical management for RA, which includes joint
arthroplasty and arthrodesis, is recommended as a last
resort.
Silicone implants have been used for many years to
replace destroyed MCP joints in the rheumatoid hand.
Historically, much of the evidence regarding the effective-
ness of silicone metacarpophalangeal arthroplasty (SMPA)
has relied on low (level 3–4) evidence from retrospective
cohorts or case series (1–13). Prospective studies offered
higher evidence (level 2), but these studies were hampered
by small study sample sizes (N ranged from 12–21 pa-
tients) (14–17). More recently, a high level of evidence
(level 1) has come from 2 randomized controlled trials
(RCTs) that compared SMPA to other implants (18,19).
The sample sizes for these RCTs were small, ranging from
33–52 patients, whereas the retrospective studies ranged
from 28–264 patients. Followup time varied by study type
with retrospective studies having longer followup (average
range 2–14 years), whereas prospective studies (average
range 1–3 years) and RCTs (range 1–2 years) had shorter
followup. None of the studies used a control group
consisting of patients who were managed medically with-
out SMPA. The majority of studies focused on physical
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measurements, such as ﬁnger arc of motion and degree
of ulnar drift, to assess outcomes. Overall, the results from
these studies report that SMPA improves function of
the rheumatoid hand (12). The degree of ulnar drift, exten-
sor lag, and the arc of motion in ﬁnger joints show im-
provement after SMPA, but grip and pinch strength do
not (1,2,8,10,16). Many studies evaluated health-related
quality of life (HRQOL) using subjective assessments by
surgeons or unvalidated questionnaires. Based on these
measures, favorable outcomes were reported in hand func-
tion, activities of daily living (ADL), pain, aesthetics, and
patient satisfaction (1,2,4–10,13,16).
The disparity between the results from functional mea-
surements such as grip and pinch strength and patient-
reported function fuels the ongoing debate regarding the
true effectiveness of SMPA. For example, previous studies
have found that rheumatologists and hand surgeons dis-
agree on the effectiveness of hand surgery for RA patients
(20,21). In a national survey of these 2 specialties, 34% of
rheumatologists compared to 83% of hand surgeons be-
lieve SMPA improves hand function for RA patients. This
disagreement in treatment options may partially explain
the large variations in the surgical management of the
rheumatoid hand in the US (22,23). It has been suggested
that patients choose surgery to improve the appearance of
the hands rather than improve function or lessen pain.
Moreover, satisfaction with surgery has been found to be
closely correlated with hand appearance (24,25). Finally,
although these implants have been used for more than 4
decades, the true complication rate of these implants is
still unknown.
To better understand outcomes following SMPA, we
conducted a multicenter prospective cohort study compar-
ing RA patients with severe MCP joint deformities who
elect to undergo SMPA to those who do not undergo
SMPA. The inclusion of the nonsurgical control group was
one of several unique aspects of this study. Outcome mea-
sures included both validated HRQOL questionnaires
and standardized hand function tests. Lastly, this study
achieved the unusual collaboration of rheumatologists and
hand surgeons. The speciﬁc aim of the study is to assess
the effectiveness of SMPA in RA patients with MCP joint
deformity in order to provide high-level evidence for or
against the procedure and to determine the long-term ben-
eﬁt of SMPA. This study presents the results from the
3-year followup after surgery or enrollment.
PATIENTS AND METHODS
The institutional review boards of all 3 study sites ap-
proved the protocol for this study. All subjects enrolled in
the study were informed about the study requirements and
signed consent forms. A detailed description of the study
methods has been previously published (26).
Study sample. RA patients were referred by their rheu-
matologists to hand surgeons to 1 of the following 3 study
sites: University of Michigan (Ann Arbor), Curtis National
Hand Center (Baltimore, Maryland), and Pulvertaft Hand
Centre (Derby, UK). All of the study sites are compre-
hensive centers dedicated to the treatment of upper ex-
tremity disorders and have a large rheumatology program,
which enhanced patient accrual for this study. In addition,
the heterogeneous racial composition from the 3 study
sites ensures that minority groups are represented in this
study. Inclusion criteria were 1) diagnosis with RA by a
rheumatologist, 2) age 18 years, 3) ability to complete
questionnaires in English, and 4) severe deformity at the
MCP joints as determined by the sum of the average
ulnar deviation and average extensor lag of the 4 ﬁngers.
The sum of these 2 measurements had to be 50°. This
cutoff was determined by an expert panel to be the mini-
mum level of deformity that would be needed before sur-
gery would be considered. Exclusion criteria were 1) se-
vere medical conditions precluding surgery (e.g., severe
coronary artery disease, uncontrolled diabetes mellitus,
chronic renal failure), 2) concomitant extensor tendon rup-
tures and MCP joint disease, 3) swan-neck or boutonniere
deformities that require surgical correction, 4) patients
who have undergone previous MCP joint replacement on
the study hand, and 5) patients who have begun taking
disease-modifying antirheumatic drugs (DMARDs) in the
past 3 months.
Study design. This study applied a prospective cohort
design. Patients were not randomized due to strong patient
preferences regarding their choice for having surgery. A
pilot study at 2 of the 3 sites was completed before the start
of the study to determine if patients would agree to be
randomized. Most patients would not consent to random-
ization because they have an inherent preference whether
to have or not to have surgery. Therefore, patients chose
whether or not to have surgery. If both hands were af-
fected, patients chose the hand on which to have surgery.
Surgical subjects had SMPA performed on all 4 ﬁngers.
The nonsurgical group chose which hand was the study
hand. Subjects in the nonsurgical group could cross over
to the surgical group after 1 year of enrollment in the
study. Additionally, surgical subjects could elect to have
surgery on their other affected hand 1 year after having
surgery on the ﬁrst hand. In addition to the time of enroll-
ment, patients were assessed at 6 months, 1 year, 2 years,
and 3 years postsurgery or enrollment. All outcomes were
assessed at each followup visit. Patients were contacted by
phone and/or mail for followup visits and were considered
lost to followup if there was no response after numerous
attempts.
Signiﬁcance & Innovations
● The study provides high-level long-term evidence
on silicone metacarpophalangeal arthroplasty
results.
● This is a large collaborative study between rheu-
matologists and hand surgeons.
● The study uses a hand-speciﬁc outcomes question-
naire to measure results.
● Surgical subjects are compared to a nonsurgical
cohort with similar levels of deformities.
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Outcome measures. Outcomes were assessed at enroll-
ment, 6 months, 1 year, 2 years, and 3 years after the
surgery date for the surgical cohort or the enrollment date
for the nonsurgical cohort. All functional measurements
were performed on both hands, but the results presented
are for the surgical or study hand. A certiﬁed hand thera-
pist conducted the functional assessments that included
grip strength, lateral pinch, 2-point pinch and 3-point
pinch, and range of motion measurements for all the joints
in each ﬁnger and for the wrist. The motion measurements
included the degree of ulnar drift (angle of the ﬁngers at
the MCP joint), extensor lag (degree to which ﬁngers lag
when fully extended), and arc of motion (difference in
degrees at joints when ﬁngers are extended and ﬂexed).
The research coordinator administered the Jebsen-Taylor
Test, which simulates ADL (27). Subjects performed vari-
ous everyday type activities, including the following:
1) turning over 3- by 5-inch cards, 2) picking up small
objects and placing them in a container, 3) stacking check-
ers, 4) simulated eating, 5) moving large empty cans, and
6) moving large weighted cans. The writing portion of
the test was excluded, and the time to complete the tasks
is measured in seconds. Two questionnaires were used:
the Michigan Hand Outcomes Questionnaire (MHQ)
(28,29) and the Arthritis Impact Measurement Scales 2
(AIMS2) (30). The MHQ is a hand-speciﬁc questionnaire,
whereas the AIMS2 measures overall health status in RA
patients. The MHQ contains 6 domains (function, ADL,
work, pain, aesthetics, and satisfaction) and scores range
from 0–100, with higher scores indicating better perfor-
mance with the exception of the pain scale. For the pain
scale, a higher score indicates more pain. The satisfaction
domain asks about satisfaction with the overall perfor-
mance of the hand and wrist. The MHQ queries subjects
about both hands, but only the results for the surgical or
study hand are analyzed. The AIMS2 contains 4 domains
(physical, affect, symptom, and social interaction) and
domain scores range from 1–10, with lower scores indicat-
ing better health status. Both questionnaires are validated
for RA.
Complications. Subjects were assessed for complica-
tions such as infections and deformities/fractures of the
implants at followup visits. The integrity of the MCP joint
implants in surgery subjects was assessed using radio-
graphs at 6 months and 3 years after surgery. Each implant
was categorized using the protocol by Bass et al (31) as
intact, deﬁnitely fractured, or severely deformed. Radio-
graphs were reviewed by 2 of the hand surgeons who were
blinded to the study subjects and the subjects’ study site.
When the surgeons disagreed on their assessments, they
worked together to achieve consensus. When consensus
could not be reached, a third hand surgeon made the
decision regarding fractures and/or deformities. Deaths
were reported to the institutional review boards for each
site.
Statistical analysis. The distribution of demographic
variables and other baseline variables was compared be-
tween the surgical and nonsurgical groups using the
2-sample t-tests for continuous variables and chi-square
tests for categorical variables. Because nonsurgical group
subjects were allowed to cross over their treatment groups,
all outcome data were censored beyond the time the study
hand of the nonsurgical group patient was treated by
SMPA. Baseline data including demographic and baseline
values of the outcome variables were assessed for missing
data. Baseline characteristics were also compared between
those who were lost to followup and those who were not.
For all outcome measures of interest, means and 95%
conﬁdence intervals at each followup time were calculated
by the study group. Unadjusted mean changes from base-
line in various outcome measures between the surgical
versus nonsurgical group at the 3-year followup time were
calculated. Random-effects regression models were used
to estimate and compare the 3-year outcomes between the
2 groups. For each outcome variable, the model used the
baseline and 3-year outcome values as the dependent vari-
able and an indicator for the surgical group, an indicator
for 3-year time, and an interaction term of indicators of
3-year time by surgical group. Because of the baseline
differences between the 2 groups, the models were also
adjusted for the baseline values of the outcome variable,
age, baseline severity (dichotomized as severe or not based
on degree of deformity), education (high school and lower
versus higher), income ($50,000 versus lower), sex, and
study site. All unadjusted and adjusted mean differences
were calculated so the positive values corresponded to
greater improvement in the surgical group relative to
the nonsurgical group. We also obtained the propensity-
stratiﬁed estimates of the between-group differences in
3-year outcomes (32). Propensities were estimated using
a logistic regression model with receipt of SMPA as the
dependent variable, and with all baseline covariates and
baseline values of the outcome variables as predictors. For
baseline variables with missing values, such as education
and income, the variable was encoded for an extra level
corresponding to those patients who are missing the co-
variates, and squared terms for continuous variables and
appropriate interactions terms were also included.
We used multiple imputation method to account for
missing covariates as well as missing outcomes (33). Five
imputed data sets were created using all available baseline
covariates we suspected or found to be relevant to missing
data mechanism, including rheumatoid medication types
used (DMARDs, biologic agents, or antiinﬂammatories),
whether the study hand was a dominant hand or not,
number of comorbid medical conditions, as well as demo-
graphic variables. The imputations also used all longitu-
dinally measured outcome data and accounted for the
correlation between a patient’s longitudinally measured
outcome data. Any imputed values outside of plausible
range were truncated with the proper values. For the non-
surgical group patients who later received SMPA on their
study hand, their outcome data after their receipt of SMPA
were imputed based on all data prior to the time of receipt
of their SMPA. Across the imputed data sets, covariate-
adjusted between-group mean differences were estimated
using the random-effects model, and the estimates were
combined using Rubin’s combining rules (34). All analyses
including multiple imputations were performed using
Stata 11.2 software (StataCorp).
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RESULTS
A total of 162 subjects (67 surgical and 95 nonsurgical)
were enrolled in the study. Two control subjects chose to
have surgery on the study hand after 1 year, and 10 surgi-
cal subjects elected to have surgery on their other affected
hand 1 year after having the initial SMPA on the study
hand. The 1-year results have been presented previously
(26). Due to withdrawals (n  9), deaths (n  7), losses to
followup (n  22), and missing data (n  9), 3-year data
were available in 42 surgical (63%) and 73 (77%) nonsur-
gical subjects (including 2 subjects who had surgery on
their study hand prior to their 3-year followup time)
(Figure 1).
Baseline demographic information by surgical status is
shown in Table 1. Baseline data were missing for 5%
patients except for income (8% had missing income). The
2 study groups were not signiﬁcantly different at baseline
in terms of age, race, education, and income. The surgical
group had a lower percentage of men compared to the
nonsurgical group. Those who were missing versus not
missing 3-year outcome data were not different with re-
spect to various demographic variables, but having miss-
ing data depended on the baseline values of the outcomes
and the magnitude of the change in the outcome values.
Speciﬁcally, in both the nonsurgical and surgical groups,
those who were missing the 3-year MHQ data tended to
have more severe baseline symptoms than those not miss-
ing the 3-year followup data (P  0.02 based on baseline
MHQ). In addition, in the surgical group, greater improve-
ment in MHQ values from baseline to 2 years was associ-
ated with a greater likelihood of missing the 3-year MHQ
outcome data (P  0.03), and therefore the completers-
only analysis (e.g., analysis of crude change) was expected
to give a smaller effect associated with surgical group.
Table 1. Comparison of demographic values for surgical versus nonsurgical subjects*
Demographic variables
SMPA
(n  67)
Non-SMPA
(n  95) P
Age, mean  SD years 60  8 62  11 0.24
Male, no. (%) 12 (18) 32 (35) 0.03
White race, no. (%)† 58 (94) 79 (86) 0.14
High school degree or less, no. (%)† 35 (56) 38 (41) 0.07
Income $50,000, no. (%)† 47 (77) 60 (68) 0.24
* SMPA  silicone metacarpophalangeal joint arthroplasty.
† Eight (5%) participants are missing race and education data, and 13 (8%) are missing income data.
Figure 1. Study ﬂow chart.
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Surgical subjects were signiﬁcantly different from non-
surgical subjects for the majority of baseline measurements
(Table 2). In particular, surgical subjects had worse hand
functioning as measured with the MHQ; mean overall
MHQ score was 37 in the surgical group and 56 in the
nonsurgery group. Figure 2 plots the mean overall MHQ
scores, aesthetics, satisfaction, and pain domain scores
over time by the study groups. In general, hand outcomes
of the surgical patients improved from their initial state to
a level similar to the control group by 6 months, and this
improvement was maintained to 3 years. In the aesthetics
and satisfaction domains, the surgical patients improved
to substantially higher levels than those of the nonsurgical
patients at 6 months, but the domain scores slowly de-
creased after 1 year. AIMS2 subscales all showed signiﬁ-
cantly worse health in surgical than in nonsurgical pa-
tients at baseline, and over the 3 years of followup the
surgical group did not show better outcomes than the
nonsurgical group.
The degrees of ulnar drift and lateral pinch strength
were similar at baseline between the 2 study groups, but
grip and tip and palmar pinch strength were worse in
surgical patients compared to nonsurgical patients. Stan-
dard functional measurements of grip strength, pinch
strength, and ulnar drift and extensor lag showed different
responses to treatment. For example, grip strength showed
some improvement over time in both groups, but the sur-
gical group still showed less strength compared to non-
surgical subjects over time. No improvement was seen
for all 3 types of pinch strength (key, 2-, and 3-point) over
the entire time period. The most dramatic results were
seen for degree of ulnar drift, extensor lag, and arc of
motion, where the surgical group showed signiﬁcant im-
provement after SMPA, which remained through the 3
years of followup time, and the nonsurgical group showed
little change.
At 3 years, the surgical group showed signiﬁcant im-
provement from baseline in MHQ scores, whereas the non-
surgical group showed minimal to no improvement (Table
3). The between-group difference at 3 years from baseline
was highly signiﬁcant for the overall MHQ score as well
as the function, ADL, aesthetics, and satisfaction domains,
all showing greater improvement in hand outcomes in the
SMPA group than in the nonsurgical group. The between-
group difference estimated using the imputed data gave
similar ﬁndings, although only ADL was highly signiﬁ-
cant. For the propensity-stratiﬁed estimates, the propen-
sity model had an area under the receiver operating curve
of 0.91. The propensities were trimmed for nonoverlap-
ping ranges, which led to a much reduced sample size of
88 patients, and of those, only 59 patients provided 3-year
MHQ data. Despite the much smaller sample size, the
propensity-stratiﬁed estimate of the between-group differ-
ence of the 3-year MHQ overall summary score was 14.8
Table 2. Mean scores for surgical (SMPA) vs. nonsurgical subjects*
Preoperative 2-year 3-year
SMPA Non-SMPA SMPA Non-SMPA SMPA Non-SMPA
MHQ† n  63 n  93 n  48 n  79 n  40 n  71
Function 37  22 58  19‡ 62  19 58  22 59  19 58  21
ADL 34  26 59  24‡ 58  29 61  25 55  27 61  27
Work 41  22 59  23‡ 54  27 61  26 51  28 61  27
Pain 49  26 36  25§ 36  25 32  25 38  26 31  24
Aesthetics 33  22 47  24‡ 66  23 53  21 60  21 54  20
Satisfaction 27  20 47  25‡ 61  27 51  25 55  25 53  25
Overall 37  17 56  19‡ 61  21 59  20 57  20 59  21
AIMS2¶ n  63 n  93 n  48 n  79 n  40 n  71
Physical 4.0  2.4 2.5  1.9‡ 3.3  2.2 2.5  2.0 3.4  2.3 2.6  2.2
Affect 4.2  1.9 3.1  1.8‡ 3.7  1.8 2.9  1.7 3.7  2.3 2.7  1.6
Symptom 5.7  2.8 4.3  2.4§ 4.6  2.4 3.9  2.3 5.0  2.3 4.0  2.5
Social interaction 4.1  2.0 3.6  1.4§ 4.1  2.1 3.7  1.3 4.1  2.1 3.5  1.6
Objective measurements n  67 n  95 n  45 n  74 n  39 n  66
Grip strength, kg 5.4  5.2 8.6  7.4§ 6.1  4.4 10.6  7.5 6.0  4.2 9.7  5.9
Key (lateral) pinch, kg 3.5  2.2 4.0  1.8 3.2  1.9 3.7  1.9 3.0  2.0 3.4  1.8
2-point (tip) pinch, kg 2.5  1.6 3.1  1.5§ 2.4  1.5 2.9  1.5 2.2  1.4 2.7  1.3
3-jaw (palmar) pinch, kg 2.5  1.5 3.2  1.4§ 2.5  1.4 3.2  1.5 2.4  1.5 2.7  1.2
Jebsen-Taylor (seconds)# 55  27 43  12‡ 43  11 39  10 44  13 40  12
Ulnar drift# 37  15 35  15 14  9 33  16 14  11 34  17
Extensor lag# 65  23 47  18‡ 25  14 48  23 29  15 53  21
MCP arc of motion 20  15 37  18‡ 33  17 33  20 30  14 29  16
PIP arc of motion 56  27 70  22‡ 66  25 67  22 64  26 67  21
* Values are the mean  SD unless indicated otherwise. SMPA  silicone metacarpophalangeal joint arthroplasty; MHQ Michigan Hand Outcomes
Questionnaire; ADL  activities of daily living; AIMS2  Arthritis Impact Measurement Scales 2; MCP  metacarpophalangeal joint; PIP  proximal
interphalangeal joint.
† All MHQ domain scores and overall score can range from 0–100, and higher scores correspond to better outcomes, except for pain, where higher
scores correspond to greater pain.
‡ P  0.001 for between-group differences at baseline.
§ P  0.05 for between-group differences at baseline.
¶ All AIMS2 subscales can range from 0–10, and higher scores correspond to worse outcomes.
# Higher values correspond to worse outcomes.
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(P  0.002). Similarly, the propensity-stratiﬁed estimates
of the MHQ domains were 17.6 (P  0.002) for function,
15.7 (P  0.001) for ADL, 7.1 (P  0.27) for work, 6.2 (P 
0.37) for pain, 21.1 (P 0.001) for aesthetics, and 21.2 (P
0.003) for satisfaction.
The AIMS2 score changes were minimal, with no signif-
icant between-group differences (Table 3). Objective mea-
sures such as grip and pinch strength did not show greater
improvement for the surgical group compared to the non-
surgical group, except for the Jebsen-Taylor Test (Table 4).
For each of ulnar drift, extensor lag, MCP arc of motion,
and proximal interphalangeal arc of motion, signiﬁcant
improvements were seen in the SMPA group, whereas
worsening was seen in nonsurgical groups in general, and
the adjusted between-group differences were signiﬁcant at
3 years, using both all available data and multiple-imputed
data.
We analyzed the outcomes of the study (surgical) hand
and the control (nonsurgical) hand in the SMPA group to
determine if we would ﬁnd comparable results to those
Figure 2. Means and 95% conﬁdence intervals from baseline to 3 years for select Michigan Hand Outcomes Questionnaire (MHQ) scores,
surgical versus nonsurgical subjects. SMPA  silicone metacarpophalangeal arthroplasty.
Table 3. Crude and adjusted changes from baseline to 3 years for MHQ and AIMS2 scales*
Crude change Adjusted change
Adjusted
difference†
Adjusted
difference with
imputation‡SMPA Non-SMPA SMPA Non-SMPA
MHQ§ n  40 n  71 n  40 n  71 n  111 n  162
Overall 18 (12, 24) 2 (0.4, 5) 19 (15, 22) 3 (0.1, 5) 16 (12, 21)¶ 14 (1, 30)
Function 21 (13, 28) 2 (5, 1) 21 (17, 26) 1 (5, 2) 22 (17, 28)¶ 18 (0, 36)#
ADL 17 (12, 23) 2 (2, 5) 18 (14, 22) 2 (1, 5) 16 (11, 21)¶ 21 (11, 32)¶
Work 8 (1, 14) 2 (2, 7) 8 (3, 13) 3 (1, 7) 6 (1, 12) 10 (12, 33)
Pain 9 (0.8, 18) 3 (2, 7) 10 (4, 15) 3 (1, 8) 6 (1, 13) 8 (14, 30)
Aesthetics 28 (19, 37) 5 (0.6, 9) 28 (23, 33) 5 (1, 9) 23 (16, 29)¶ 20 (4, 37)#
Satisfaction 28 (19, 36) 4 (0.5, 9) 28 (22, 33) 4 (0.0, 9) 24 (17, 31)¶ 19 (4, 33)#
AIMS2** n  40 n  71 n  40 n  71 n  111 n  162
Physical 0.1 (0.2, 0.5) 0.0 (0.3, 0.2) 0.2 (0.1, 0.5) 0.0 (0.3, 0.2) 0.2 (0.1, 0.6) 0.7 (1.1, 2.5)
Affect 0.3 (0.3, 0.8) 0.2 (0.1, 0.5) 0.3 (0.1, 0.6) 0.2 (0.1, 0.5) 0.1 (0.4, 0.5) 0.3 (1.1, 1.8)
Symptom 0.7 (0.1, 1.3) 0.1 (0.4, 0.5) 0.7 (0.2, 1.2) 0.1 (0.3, 0.5) 0.6 (0.0, 1.2) 0.2 (1.3, 1.8)
Social interaction 0.1 (0.4, 0.6) 0.0 (0.3, 0.3) 0.1 (0.3, 0.4) 0.0 (0.3, 0.3) 0.1 (0.3, 0.6) 0.2 (1.0, 1.5)
* Values are the mean (95% conﬁdence interval) unless indicated otherwise. Using random-effects model with baseline and year 3 outcome values as
the dependent variable and adjusted for baseline values of the outcome variable, age, sex, baseline severity stage, education level, income level, study
site, 3-year indicator, silicone metacarpophalangeal joint arthroplasty (SMPA) group indicator, and SMPA group by 3-year time interaction. MHQ 
Michigan Hand Outcomes Questionnaire; AIMS2  Arthritis Impact Measurement Scales 2; ADL  activities of daily living.
† Between-group differences at 3 years; positive scores reﬂect better outcomes in SMPA group relative to nonsurgical group.
‡ Based on 5 imputations.
§ Positive values reﬂect improvement; calculated as 3-year minus baseline values for all scales, except pain, where it is baseline minus 3-year values.
¶ P  0.001.
# P  0.05.
** Changes are calculated as baseline minus 3-year values so that positive values reﬂect improvement.
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found in Tables 3 and 4. The analysis looked at the differ-
ence in mean scores from baseline to 3 years for the 2
hands (Supplementary Table 1, available in the online
version of this article at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)2151-4658). The results were simi-
lar to the analyses comparing SMPA and nonsurgical sub-
jects; signiﬁcant differences were found between study
and control hands in the change in mean values from
baseline to 3 years for arc of motion, ulnar drift, extensor
lag, and overall MHQ score.
We also compared results by study center. Patients in all
centers showed signiﬁcant improvement in MHQ, but
even after adjusting for covariates, including the use of
biologic agents, the 2 US sites showed signiﬁcantly greater
improvement than the UK site. A previous article noted
the differences between the US and the UK sites, which
were attributed to differences in the health care systems
between countries (35).
Regarding adverse events, 1 patient had an infection
from a proximal interphalangeal joint fusion. Two patients
required revision SMPA due to ulnar drift and dislocation
of the implant, respectively. Fractures and deformities of
the silicone implant were assessed using radiographs. Of
the 69 surgical cases, 42 had radiographs taken at 3 years
after surgery. Four (9.5%) subjects had deﬁnite fractures in
at least 1 ﬁnger, and 7 (16.7%) had at least 1 severely
deformed joint. Seven subjects died prior to the 3-year
assessment. None of the deaths were determined to be
related to the study.
DISCUSSION
The evidence-based medicine movement stresses the im-
portance of ﬁnding the highest available evidence and
combining that information with physician experience
and patient preferences when determining the course of
treatment. There is a substantial amount of high-level ev-
idence through RCTs that medications can slow or stop the
progression of RA. Surgery, and in particular SMPA, can-
not prevent the physical damage of RA, but there is some
evidence that it can restore function to the hands of af-
fected RA patients. The results presented in this article are
from the largest collaborative study between hand sur-
geons and rheumatologists on SMPA.
The results from extended followup of this cohort of
surgical and nonsurgical subjects showed that the beneﬁts
of SMPA continue through 3 years after surgery. The main
outcome of the study is hand function as assessed using
the MHQ. Surgical patients, when compared to nonsurgi-
cal patients, reported signiﬁcant improvements from the
MHQ in hand function, ADL, aesthetics, and satisfaction
over time. For example, the average scores for these do-
mains increased by 22, 16, 23, and 24 points, respectively,
after adjusting for other variables. The minimum clinically
important difference calculated for the MHQ function and
ADL domains are 13 and 3, respectively (36). Our results
for these domains are well over this threshold. Previous
studies have reported improvements in pain, aesthetics,
satisfaction, ADL, and function after SMPA. However,
these results were not based on validated HRQOL ques-
tionnaires.
Surgical subjects as compared to nonsurgical subjects
show a dramatic improvement in the degree of ulnar drift,
extensor lag, and arc of motion at the MCP joint. We found
an average 20° improvement in ulnar drift and 30° im-
provement in extensor lag over 3 years. Previous studies
that did compare objective measures before and after sur-
gery had similar results. These studies found ulnar drift to
improve from 9–30° postoperatively and extensor lag im-
proved from 34–47° (1,2,8,10,11,16). Arc of motion in our
study increased 9° on average over 3 years, whereas other
studies have reported from 11 to 34° postoperative im-
provement (1–5,7,8,10,11,16,17). The lack of improvement
in grip strength in this study has been conﬁrmed previ-
ously (8). SMPA allows the patient to open and close their
hands more easily, but does not increase the strength of the
hand or pinch of the ﬁngers. There is no reference standard
for determining hand function, but research has shown
that patient-reported outcomes, such as those reported in
the MHQ, are more sensitive patient-oriented measures of
outcomes than traditional measures such as grip and pinch
strength (37).
Complications from SMPA in our cohort were minimal
at 3 years. One complication that can arise from SMPA is
implant fracture. Previous studies of implant fracture spe-
ciﬁcally for the silicone implant have found rates ranging
from 0–67% (5–8,10,11,14,28,29,31,38–42). Overall, the
3-year fracture rate of 9.5% for this cohort is low.
The most important outcome for rheumatoid patients
and hand surgeons considering surgery is improved func-
tion. Our 3-year results have demonstrated that the SMPA
procedure will improve function and ADL and restore the
appearance of severely deformed rheumatoid hands. More
importantly, the baseline adjusted difference between
SMPA versus nonsurgically treated hands remained sig-
niﬁcant, indicating that at 3 years after surgery, SMPA-
treated patients continued to have better hand outcomes
than comparable nonsurgically treated patients.
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